Cargando…
Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England
BACKGROUND: The coronavirus pandemic resulted in many changes which had the potential to impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine), including changes in the prescribing and dispensing of OAT and patterns of drug availability and use. We aimed to assess the im...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531664/ https://www.ncbi.nlm.nih.gov/pubmed/36265326 http://dx.doi.org/10.1016/j.drugpo.2022.103877 |
_version_ | 1784801948364439552 |
---|---|
author | Aldabergenov, D Reynolds, L Scott, J Kelleher, MJ Strang, J Copeland, CS Kalk, NJ |
author_facet | Aldabergenov, D Reynolds, L Scott, J Kelleher, MJ Strang, J Copeland, CS Kalk, NJ |
author_sort | Aldabergenov, D |
collection | PubMed |
description | BACKGROUND: The coronavirus pandemic resulted in many changes which had the potential to impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine), including changes in the prescribing and dispensing of OAT and patterns of drug availability and use. We aimed to assess the impact of the first lockdown (initiated March 23rd 2020) on methadone- and buprenorphine-related deaths in England in people both prescribed and not prescribed OAT using data from the National Programme on Substance Abuse Deaths. METHODS: This was a retrospective post-mortem toxicology study of OAT-related deaths which occurred in the 3-month period March 23rd to June 22nd in the years 2016-2020. Provisional data regarding numbers accessing treatment for opioid use disorder was provided by the National Drug Treatment Monitoring System. RESULTS: We found a 64% increase in methadone-related deaths in March to June 2020 compared to March to June 2019 (2019 n = 96; 2020 projected n = 157). There were increases in the mortality rate of both in-treatment decedents (22% increase; 2019 n = 45; an exponential smoothing model of the 2016-19 trend [α=0.5] predicted 44 deaths in 2020, 55 were reported) and decedents not prescribed methadone (74% increase; 2019 n = 46; 2016-19 trend predicted 43 deaths in 2020, 80 were reported). There was no increase in buprenorphine-related deaths (2019 n = 9/529; 2020 n = 11/566). There were no changes in the numbers of deaths where other opioids or multiple substances were detected, or in methadone levels detected. Numbers of people accessing treatment for opioid use disorder in 2020 did not decrease relative to previous years (p >0.05). CONCLUSIONS: Methadone-related deaths in non-prescribed individuals, but not prescribed individuals, increased considerably above the annual trend forecast for 2020 during the first COVID-19 lockdown in England. Further studies are thus needed to understand this difference. |
format | Online Article Text |
id | pubmed-9531664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95316642022-10-05 Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England Aldabergenov, D Reynolds, L Scott, J Kelleher, MJ Strang, J Copeland, CS Kalk, NJ Int J Drug Policy Research Paper BACKGROUND: The coronavirus pandemic resulted in many changes which had the potential to impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine), including changes in the prescribing and dispensing of OAT and patterns of drug availability and use. We aimed to assess the impact of the first lockdown (initiated March 23rd 2020) on methadone- and buprenorphine-related deaths in England in people both prescribed and not prescribed OAT using data from the National Programme on Substance Abuse Deaths. METHODS: This was a retrospective post-mortem toxicology study of OAT-related deaths which occurred in the 3-month period March 23rd to June 22nd in the years 2016-2020. Provisional data regarding numbers accessing treatment for opioid use disorder was provided by the National Drug Treatment Monitoring System. RESULTS: We found a 64% increase in methadone-related deaths in March to June 2020 compared to March to June 2019 (2019 n = 96; 2020 projected n = 157). There were increases in the mortality rate of both in-treatment decedents (22% increase; 2019 n = 45; an exponential smoothing model of the 2016-19 trend [α=0.5] predicted 44 deaths in 2020, 55 were reported) and decedents not prescribed methadone (74% increase; 2019 n = 46; 2016-19 trend predicted 43 deaths in 2020, 80 were reported). There was no increase in buprenorphine-related deaths (2019 n = 9/529; 2020 n = 11/566). There were no changes in the numbers of deaths where other opioids or multiple substances were detected, or in methadone levels detected. Numbers of people accessing treatment for opioid use disorder in 2020 did not decrease relative to previous years (p >0.05). CONCLUSIONS: Methadone-related deaths in non-prescribed individuals, but not prescribed individuals, increased considerably above the annual trend forecast for 2020 during the first COVID-19 lockdown in England. Further studies are thus needed to understand this difference. The Authors. Published by Elsevier B.V. 2022-12 2022-10-04 /pmc/articles/PMC9531664/ /pubmed/36265326 http://dx.doi.org/10.1016/j.drugpo.2022.103877 Text en © 2022 The Authors. Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Research Paper Aldabergenov, D Reynolds, L Scott, J Kelleher, MJ Strang, J Copeland, CS Kalk, NJ Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England |
title | Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England |
title_full | Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England |
title_fullStr | Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England |
title_full_unstemmed | Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England |
title_short | Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England |
title_sort | methadone and buprenorphine-related deaths among people prescribed and not prescribed opioid agonist therapy during the covid-19 pandemic in england |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531664/ https://www.ncbi.nlm.nih.gov/pubmed/36265326 http://dx.doi.org/10.1016/j.drugpo.2022.103877 |
work_keys_str_mv | AT aldabergenovd methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland AT reynoldsl methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland AT scottj methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland AT kellehermj methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland AT strangj methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland AT copelandcs methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland AT kalknj methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland |